Global Healthcare Leader Deploys QUOSA’s Literature Management Tools
Philadelphia, October 22, 2013
Sanofi will use QUOSA, part of Elsevier Life Science Solutions
for drug discovery and development, to support adverse event monitoring
Sanofi will use QUOSA, part of Elsevier Life Science Solutions for drug discovery and development, to support adverse event monitoring
Elsevier, a world-leading
provider of scientific, technical and medical information products and
services, today announced that Sanofi, one of the world's leading
pharmaceutical organizations, has implemented QUOSA's literature
management tools to automate adverse event monitoring. QUOSA powers the
retrieval, storage, tagging and annotation of relevant case reports, allowing for
the creation of a centralized repository of product-related scientific
literature. This centralized repository supports Sanofi's Pharmacovigilance
team in drug safety and adverse event monitoring, ensuring patient safety and
compliance with regulatory reporting requirements in all the markets in which
"Pharmaceutical companies are continually challenged to ensure regulatory compliance is met. This is no easy task with limited resources, an ever-growing number of literature articles and an increasing portfolio of drugs to be tracked. Left untamed, this presents significant risks in compliance and crucially, in patient safety," said Michael Rai, General Manager of QUOSA at Elsevier. "In response to our many conversations with Information Professionals, we have finely tuned QUOSA to complement current processes to provide a stable, efficient and scalable solution which continues to evolve with future needs. We look forward to working with Sanofi to manage this flow of information and support its Pharmacovigilance teams' work."
QUOSA provides software and services to life science companies, enabling them to centralize repositories of scientific literature related to drugs and medical devices, as well as receive alerts about new articles related to their products and other market developments. These not only help Pharmacovigilance and Medical Affairs teams carry out their work effectively and quickly, they also ensure sound information management processes and compliance with regulatory requirements.
QUOSA's pharmacovigilance solution features three elements that help companies meet their literature tracking objectives. First, Elsevier provides prompt customized professional services through its dedicated Life Sciences Integration Services team. Second, QUOSA can be used as either a desktop application or browser-based technology, facilitating secure and scalable information sharing across multiple regions. Third, QUOSA easily integrates with already existing literature resources like third-party publisher platforms, A&I databases like Embase, and document delivery vendors.
QUOSA is part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including TargetInsights®, Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, PharmaPendium® and Embase®.
# # #
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 2247